narmac - Agree that a $5 billion buyout at this time is fantasy however we are getting to the point now where BP has to be thinking of tying this company up in some way. As Mazola said a CVR of some kind including Zenith Epigenetics Ltd could make a lot of sense. As far as dilution, it doesn't necessarily need to be a given. With some up front cash (100 to 400 mil) it could tie us up now for a predetermined future price if specific results are achieved. There is the potential for RVX-208 to have in excess of $10 billion of annual sales. Sales of both RVX and ZEN drugs are projected to begin in 2021. The FA along with Zenith trial results will be out in the not to distant future. We are about to complete a financing of $4.5 mil to someone or a group that cannot sell any of these shares before 07 Jan 2018 which is after the drop dead date of 26 Dec. 2017. There would be a slim chance of shorting 3 mil shares over the next 4 months to cover their position if needed. I can't think of anyone in their right mind that would do this financing now unless they had very good comfort that there would be enough cash available to pay out this loan...soon.

Mazola may be onto something here.

dyodd

tada